Meeting
2023 ASCO Annual Meeting
Final three-year follow-up analysis of phase I/II study on tirabrutinib in patients with relapsed or refractory primary central nervous system lymphoma.
Authors
Katsunori Asai
Department of Neurosurgery, Osaka International Cancer Institute, Osaka, Japan
Katsunori Asai , Yoshitaka Narita , Motoo Nagane , Kazuhiko Mishima , Yasuhito Terui , Yoshiki Arakawa , Hajime Yonezawa , Noriko Fukuhara , Kazuhiko Sugiyama , Naoki Shinojima , Arata Aoi , Ryo Nishikawa
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Non-Hodgkin Lymphoma
Clinical Trial Registration Number
JapicCTI-173646
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 7548)
DOI
10.1200/JCO.2023.41.16_suppl.7548
Abstract #
7548
Poster Bd #
99
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Favezelimab (anti–LAG-3) plus pembrolizumab in patients with anti–PD-1–naive relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL): An open-label phase 1/2 study.
First Author: Nathalie A. Johnson
Poster
2022 ASCO Annual Meeting
Primary analysis from the phase 2 study of continuous talazoparib (TALA) plus intermittent low-dose temozolomide (TMZ) in patients with relapsed or refractory extensive-stage small cell lung cancer (ES-SCLC).
First Author: Jonathan W. Goldman
Poster
2023 ASCO Annual Meeting
Two schedules of vincristine, irinotecan and temozolomide (VIT) for patients with relapsed or refractory Ewing sarcoma: A randomized controlled phase 2 trial.
First Author: Jie Xu
Poster
2022 ASCO Annual Meeting
Subcutaneous epcoritamab with rituximab + lenalidomide (R2) in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): Update from phase 1/2 trial.
First Author: Lorenzo Falchi